Jefferies on Protagonist Therapeutics (PTGX): 'well-funded for multiple high value oral peptide pipeline'

Jefferies analyst Roger Song reiterated a Buy rating and $171.00 price target on Protagonist Therapeutics (NASDAQ: PTGX).

The analyst comments "We caught up with mgmt. Mimrylo label bodes well for rapid commercial adoption, supported by broad indication, 1st fatigue claim with Ph3 RCT data, clean safety, and SoC like monitoring. ~78% of treated PV pts are inadequately controlled, creating large opp'y. Takeda's $1-2B peak sales forecast predated strong Ph3 data and favorable label, suggesting conservatism. With two sig royalty streams, PTGX is well-funded for multiple high value oral peptide pipeline."

For an analyst ratings summary and ratings history on Protagonist Therapeutics click here. For more ratings news on Protagonist Therapeutics click here.

Shares of Protagonist Therapeutics closed at $144.33 yesterday.

You May Also Be Interested In

• Huang Calls AI 'the Great Equalizer' During G20 Event
• UBS Reiterates Sell Rating on Comstock Resources (CRK) on SOCAR Agreement
• Deutsche Bank Upgrades Sirius XM Radio (SIRI) to Buy, 'mispriced based on a large disconnect between consensus estimates and what we believe the company can achieve